Abiopharma

SIONNA THERAPEUTICS, INC. (SION)

Symbol	SION
Name	SIONNA THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	21 HICKORY DRIVE,SUITE 500, WALTHAM, Massachusetts, 02451, United States
Telephone	617-819-2020
Fax	—
Email	—
Website	https://www.sionnatx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002036042
Description	Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTRs nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models. Additional info from NASDAQ: Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTRs nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models.

2026-07-07 20:38

Fitzpatrick Jennifer 🟡 adjusted position in 10.2K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $43.60 Transaction Date: Jul 06, 2026 | Filing ID: 000006

2026-07-06 20:39

📋 JENNIFER FITZPATRICK (Officer) plans to sell 10K shares of SIONNA THERAPEUTICS, INC. (at $43.99 each, total $451K) Filed: Jul 06, 2026 | ID: 006887

2026-07-02 20:45

Director Thompson Peter A. 🔴 sold 115.8K shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.3M) Transaction Date: Jun 30, 2026 | Filing ID: 000684

2026-06-18 21:58

Director Stelzer Laurie 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000007

2026-06-18 21:48

Director Viney Joanne L. 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000002

2026-06-18 21:45

Director Thompson Peter A. 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000003

2026-06-18 21:41

RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000674

2026-06-18 21:39

Director Ruddy Marcella K. 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000010

2026-06-18 21:37

Director Resnick Joshua 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000004

2026-06-18 21:35

Director Fleming Harold Edward 🟢 acquired 17.3K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $36.73 Transaction Date: Jun 17, 2026 | Filing ID: 000002

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07108153	Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, …	Phase2	Cystic Fibrosis (CF)	Active_Not_Recruiting	2025-11-03	2026-07-01	ClinicalTrials.gov
NCT07035990	Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SIO…	Phase1	Cystic Fibrosis (CF)	Recruiting	2025-07-23	2026-06-01	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	ACTIVE_NOT_RECRUITING	NCT07108153
Placebo SION-109	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
Placebo SION-2222	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
Placebo SION-451	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-109	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-2222	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-451	Other	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
Placebo-to-match SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	RECRUITING	NCT07108153
SION-719	Other	Phase PHASE2	Cystic Fibrosis (CF)	RECRUITING	NCT07108153
Placebo-to-match SION-719	DRUG	Phase PHASE2	Cystic Fibrosis (CF)	RECRUITING	NCT07108153
SION-719	DRUG	Phase PHASE2	Cystic Fibrosis (CF)	RECRUITING	NCT07108153
Placebo SION-109	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
Placebo SION-2222	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
Placebo SION-451	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-109	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-2222	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990
SION-451	DRUG	Phase PHASE1	Cystic Fibrosis (CF)	RECRUITING	NCT07035990

Total products: 32